Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 1/20 | 0.48 |
| ▸ | CMA1 | P23946 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.42 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL490691 | 0.86 | CTSG (0.56) | CTSGCMA1FFAR4ALDH1A1LMNA | |
| SCHEMBL7885276 | 0.85 | CTSG (0.55) | CTSGCMA1FFAR4ALDH1A1LMNA | |
| SCHEMBL3408740 | 0.81 | KMT2A (0.54) | CTSGCMA1FFAR4HPGDLMNA | |
| SCHEMBL8023122 | 0.80 | FFAR4 (0.61) | FFAR4ALDH1A1LMNAPTGER1PTGER4 | |
| SCHEMBL30753448 | 0.80 | CYP4F2 (0.41) | CTSGCMA1ALDH1A1HPGDHTT | |
| SCHEMBL21715451 | 0.80 | CYP4F2 (0.41) | CTSGCMA1ALDH1A1HPGDHTT | |
| SCHEMBL27908883 | 0.79 | PTGDR (0.53) | FFAR4ALDH1A1HPGDLMNAPTGDR | |
| SCHEMBL1251863 | 0.79 | TAAR1 (0.59) | — | |
| SCHEMBL3697457 | 0.79 | LMNA (0.50) | FFAR4ALDH1A1LMNA | |
| SCHEMBL362209 | 0.78 | LMNA (0.59) | HPGDLMNAPOLBFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487121-B2 | Chromane derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-07-16 | — | — | US | disclosed |
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-12-09 | — | — | US | disclosed |
| EP-2254879-A2 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009084034-A2 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS, S. A. (CH) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | TRPV3, TRPV2, TRPV1 | CTSG 2628/4885CMA1 1807/4885FFAR4 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.